Objective-This study examined vascular actions of angiotensin 1-7 (ANG 1-7) in human atrial and adipose arterioles. Approach and Results-The endothelium-derived hyperpolarizing factor of flow-mediated dilation (FMD) switches from antiproliferative nitric oxide (NO) to proatherosclerotic hydrogen peroxide in arterioles from humans with coronary artery disease (CAD). Given the known vasoprotective properties of ANG 1-7, we tested the hypothesis that overnight ANG 1-7 treatment restores the NO component of FMD in arterioles from patients with CAD. Endothelial telomerase activity is essential for preserving the NO component of vasodilation in the human microcirculation; thus, we also tested whether telomerase activity was necessary for ANG 1-7-mediated vasoprotection by treating separate arterioles with ANG 1-7±the telomerase inhibitor 2-[[(2E)-3-(2-naphthalenyl)-1-oxo-2-butenyl1-yl]amino]benzoic acid. ANG 1-7 dilated arterioles from patients without CAD, whereas dilation was significantly reduced in arterioles from patients with CAD. In atrial arterioles from patients with CAD incubated with ANG 1-7 overnight, the NO synthase inhibitor NGnitro-l-arginine methyl ester abolished FMD, whereas the hydrogen peroxide scavenger polyethylene glycol catalase had no effect. Conversely, in vessels incubated with ANG 1-7+2-[[(2E)-3-(2-naphthalenyl)-1-oxo-2-butenyl1-yl]amino] benzoic acid, NG-nitro-l-arginine methyl ester had no effect on FMD, but polyethylene glycol catalase abolished dilation.
T he vasoactive peptide angiotensin 1-7 (ANG 1-7) has been widely studied for the past 2 decades. Largely, the protective actions of ANG 1-7 oppose the pro-oxidative, proliferative, and pressor actions of angiotensin II, making it an attractive target for cardioprotective therapies. ANG 1-7 has been demonstrated to be a potent vasodilator in multiple vascular beds; however, the majority of these studies have been performed in rodents. The vasodilator properties of ANG 1-7 have scarcely been described in humans, and those reports that do exist are conflicting. For example, Sasaki et al 1 have shown that intra-arterial infusion of ANG 1-7 significantly increases forearm blood flow in healthy subjects and that the response is blunted in hypertensive subjects, whereas Wilsdorf et al 2 conversely showed that intrabrachial ANG 1-7 infusion had no effect on forearm blood flow and also had no potentiating effect on bradykinin-induced vasodilation. In this study, we first sought to determine whether ANG 1-7 causes vasodilation in the human coronary and peripheral microcirculations and whether this response is altered in patients with coronary artery disease (CAD).
We have previously demonstrated that human atrial and adipose arterioles from subjects with CAD invoke a compensatory vasodilator pathway in response to increased intraluminal flow (flow-mediated dilation [FMD] ) and that this pathway releases endothelium-derived hydrogen peroxide (H 2 O 2 ) rather than nitric oxide (NO) as the vasoactive mediator. [3] [4] [5] [6] The long-term consequences of invoking a vasodilator pathway that repeatedly generates H 2 O 2 , a molecule that favors a proliferative and oxidative state in the endothelium, versus NO, a molecule that is antiproliferative and antiinflammatory, remain unknown. However, it could be surmised that long-term exposure to H 2 O 2 in the vascular milieu exacerbates an already damaged vascular endothelium; thus, it may be beneficial to restore NO-mediated vasodilation to promote vascular homeostasis. Previous studies have shown that plasma ANG 1-7 levels positively correlate with brachial artery FMD in human subjects, 7 and recent findings by Zhang et al 8 demonstrated that treating renal arterioles from diabetic patients with ANG 1-7 overnight restores acetylcholinemediated dilation. In light of these findings, we also tested the hypothesis that exposing human atrial vessels from subjects with CAD to ANG 1-7 would restore the NO component of the FMD response.
Telomerase is a ribonucleoprotein that has been classically described as the protein responsible for elongating telomeres at the ends of chromosomes and is a regulator of cellular senescence. However, emerging evidence indicates that telomerase also has non-nuclear roles, which include protecting against mitochondrial dysfunction. 9,10 Recently, telomerase activity has been shown to be critically involved in maintaining the NO component of vasodilation in atrial and adipose microvessels from humans with CAD. 11 Although maintaining telomerase activity may be vital to preserving the NO component of FMD in the human microcirculation, the regulation of telomerase in the human vasculature is not well understood. Proatherosclerotic factors, such as angiotensin II, have been shown to downregulate telomerase activity in several cell types, including the endothelium, by mechanisms directly related to reactive oxygen species (ROS) accumulation. [12] [13] [14] Conversely, the effect of ANG 1-7 on telomerase activity has not been described. Because ANG 1-7 largely opposes the effects of angiotensin II, and in light of the recent finding that telomerase activity is essential in maintaining NO-mediated dilation, 11 we hypothesized that ANG 1-7 exerts vasoprotective actions in the human microcirculation by increasing vascular telomerase activity.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results
Adipose and atrial resistance arterioles were obtained from 34 subjects with a clinical diagnosis of CAD and 16 subjects without known CAD. The age, sex, body mass index, location of adipose tissue, and underlying conditions of the subjects are shown in the Table. There was no age difference between the subjects in the CAD and those in the non-CAD groups (66±1.7 versus 64±3.5 years, respectively; t test, P>0.05). A total of 45 vessels were used for analysis of vasodilation in this study. The vessels had an average internal diameter of 166±8.8 μm and were constricted to 40±1.3% of their maximal diameter before assessing vasodilation. The size of vessels used between CAD and non-CAD tissues was not different, nor was the percent constriction (t test, P>0.05).
ANG 1-7 Vasodilation Is Mediated via the Mas Receptor in the Human Microcirculation
ANG 1-7 dilated both human adipose and atrial microvessels from subjects without CAD in a dose-dependent manner ( Figure 1 ). Importantly, previous studies have shown human plasma concentrations of ANG 1-7 to be in the range of 1 to 50 pmol/L, thus the concentrations of ANG 1-7 that caused measurable vasodilation were physiological. [15] [16] [17] [18] A779 significantly reduced dilation in both vascular beds. Vasodilation to the direct smooth muscle activator papaverine (10 -4 mol/L) was unaffected by the presence of A779 (≥95% dilation in all groups; t test, P>0.05 between groups; data not shown).
ANG 1-7-Mediated Vasodilation Is Reduced in Microvessels From Subjects With CAD
As shown in Figure 2 , ANG 1-7-mediated vasodilation was significantly lower in atrial and adipose microvessels from subjects with CAD than from subjects without CAD. These findings are consistent with studies performed in rodent models of cardiovascular disease, which show reduced ANG 1-7-mediated vasodilation in the aorta of spontaneously hypertensive rats 19 and in the coronary arteries from a rat model of cardiac hypertrophy. 20 The difference in ANG 1-7-mediated dilation in microvessels from CAD and non-CAD subjects is likely not because of reduced Mas receptor density, because the receptor is robustly expressed in both the endothelial and vascular smooth muscle cell layer of vessels from both CAD and non-CAD subjects ( Figure I in the online-only Data Supplement). Dilation to papaverine was unaffected by CAD (≥95% dilation in both CAD and non-CAD vessels; t test, P>0.05; data not shown).
ANG 1-7 Prevents Flow-Induced Mitochondrial H 2 O 2 Generation in Atrial Vessels From CAD Subjects
To measure mitochondrial H 2 O 2 generation, the fluorescent dye, mitochondria peroxy yellow 1 (MitoPY1), was used. It has previously been shown that mitochondrial H 2 O 2 is the primary mediator of FMD in adipose and coronary arterioles from subjects with CAD. 3, 5, 6, 11, 21 This was confirmed in Figure 3 because when flow was induced through the lumen of vehicle-treated, cannulated coronary arterioles from subjects with CAD, a significant increase in MitoPY1 fluorescence was observed. Conversely, the increase in MitoPY1 fluorescence was attenuated in vessels treated with ANG 1-7 overnight or vehicle-treated vessels that had the H 2 O 2 scavenger polyethylene glycol catalase added to the organ bath. To confirm the specificity of MitoPY1 for mitochondrial ROS, the mitochondrial electron transport chain uncoupler antimycin A caused a time-dependent increase in MitoPY1 fluorescence in separate vessels ( Figure III in the online-only Data Supplement).
ANG 1-7 Restores Physiological NO-Mediated Vasodilation in a Telomerase-Dependent Manner
Our group has previously shown that the magnitude of FMD in adipose and atrial arterioles from subjects with CAD is similar compared with subjects without CAD; however, the mediator of vasodilation switches from NO to H 2 O 2 during CAD. [3] [4] [5] [6] This finding was confirmed in Figure 4A , because polyethylene glycol catalase inhibited FMD in atrial vessels from patients with CAD, whereas NG-nitro-l-arginine methyl ester had a potentiating effect on the magnitude of FMD. The effect of NG-nitro-l-arginine methyl ester to potentiate dilation is not altogether unexpected and may be explained because endothelial nitric oxide synthase-derived NO is a physiological regulator of mitochondrial oxygen consumption and ROS formation in endothelial cells. [22] [23] [24] The FMD response in atrial arterioles from CAD subjects requires mitochondrial H 2 O 2 as the vasoactive mediator of dilation; thus, in the absence of NO, shear-induced mitochondrial ROS formation may increase more than when physiological levels of NO are present, resulting in potentiated dilation as observed in Figure 4A .
As shown in Figure 4B , overnight incubation with ANG 1-7 (10 -9 mol/L, the approximate ED 50 of ANG 1-7 in human microvessels; Figure 1 ) restored the NO component of FMD as evidenced by the observation that NG-nitro-l-arginine methyl ester abrogated vasodilation, whereas the H 2 O 2 scavenger polyethylene glycol catalase had no effect. The effect of ANG 1-7 to restore the NO component of dilation was abolished when the arterioles were coincubated with the specific telomerase inhibitor
benzoic acid (BIBR-1532; Figure 4C ), indicating that the protective effects of ANG 1-7 require telomerase activity. Incubation with BIBR-1532 alone had no effect on the mediator of FMD as polyethylene glycol catalase significantly reduced FMD ( Figure 4D ), similar to untreated atrial vessels from patients with CAD. BIBR-1532 is the most specific pharmacological inhibitor of human catalytic subunit of telomerase (TERT) currently available (reviewed by Phatak and Burger 25 ), and cytotoxicity in TERT-treated cells has not been observed using the dose reported here. 26 Furthermore, BIBR-1532 does not directly affect endothelial nitric oxide synthase mRNA, protein expression, or NO levels in human endothelial cells 11 or have an acute effect on mitochondrial ROS in human microvessels ( Figure III in the online-only Data Supplement), thus the effects of BIBR-1532 on the mechanism of FMD are most likely because of its telomerase-inhibiting effects and not off-target effects, which neither reduce endothelial nitric oxide synthase expression/activity nor acutely increase mitochondrial ROS.
Effects of ANG 1-7 on Endothelial TERT Expression and Telomerase Activity
As shown in Figure 5A , TERT mRNA is significantly increased in cultured human coronary artery endothelial cells treated overnight with ANG 1-7 (16-20 hours; 10 -9 mol/L). ANG 1-7 treatment also caused a significant increase in telomerase activity in cultured human coronary artery endothelial cells as assessed and quantified by modified telomeric repeat amplification protocol assay using droplet digital polymerase chain reaction ( Figure 5B ). ANG 1-7 treatment also caused a significant increase in TERT protein expression as assessed by Western blot analysis ( Figure 5C ). Together, these data indicate that ANG 1-7 increases telomerase activity by increasing transcription and translation of TERT, the catalytic subunit of telomerase. 
Discussion
There are 4 novel findings in this study. First, we show that ANG 1-7 is a potent vasodilator in both the human coronary and peripheral microcirculations and that this response is dependent on the Mas receptor. Second, ANG 1-7 exerts cardioprotective effects by restoring the NO component of FMD in coronary microvessels from humans with CAD. These vessels typically invoke compensatory H 2 O 2 -mediated vasodilation in response to increased flow. [3] [4] [5] [6] The observed changes induced by ANG 1-7 are endothelial in nature because smooth muscle function (tested by papaverine) was not altered. Third, the protective actions of ANG 1-7 on the human endothelium require telomerase activity because the protective effects of ANG 1-7 are completely inhibited in the presence of BIBR-1532, a specific inhibitor of telomerase activity. Last, the mechanism of action of ANG 1-7 seems to be via increased telomerase activity, which is induced (at least in part) via transcriptional activation of TERT, the catalytic subunit of telomerase.
Our understanding of the role of the renin-angiotensin system in cardiovascular homeostasis is continually evolving, but the general consensus is that the vasoprotective angiotensin-converting enzyme (ACE) 2-ANG 1-7-Mas receptor axis opposes many of the actions of the classically defined ACE-angiotensin II-angiotensin type 1 receptor (AT1) axis ( Figure 6 ). Much of the data that examine the beneficial cardiovascular actions of the ANG 1-7-Mas receptor axis come from animal models, with a limited number of studies evaluating the direct actions of ANG 1-7 in humans. An important observation made by Zisman et al 27 demonstrated a putative role for ANG 1-7 in the human heart because intracoronary infusion of angiotensin I (a precursor for both angiotensin II and ANG 1-7) resulted in a marked increase in ANG 1-7. Another important observation from that study was that ANG 1-7 generation from angiotensin I was dependent on angiotensin II as a substrate, as ANG 1-7 formation was suppressed by coadministration of enalaprilat, an ACE inhibitor. Although that study did not examine a functional role for ANG 1-7, it importantly showed that formation of ANG 1-7 also results in a net reduction of angiotensin II in the human heart.
ACE inhibitors are a front-line therapeutic to combat high blood pressure and congestive heart failure, and much of the blood pressure-lowering and cardioprotective effects of ACE inhibitors are attributed to their ability to lower plasma angiotensin II levels. Interestingly, many studies have shown that ACE inhibitors also dramatically increase plasma ANG 1-7 levels (between 5-and 25-fold) in both animals [28] [29] [30] [31] and humans. 32 To what degree the beneficial effects of ACE inhibitors can be attributed to their angiotensin II-lowering effects versus their ability to increase ANG 1-7 levels remains to be determined. Interestingly, in hypertensive humans treated with captopril, subjects who had the largest increases in plasma ANG 1-7 concentrations also had the greatest reductions in diastolic blood pressure. 32 Our results show clear evidence that ANG 1-7 both potently dilates the human coronary microcirculation and exerts a chronic vasoprotective role by promoting NO-mediated vasodilation during disease. Taken together with the recent study by Zhang et al 8 that showed that exogenous ANG 1-7 treatment restores vasodilation in renal arterioles from diabetic patients, it is conceivable that increased ANG 1-7 levels in the plasma during ACE inhibitor therapy may significantly contribute to their cardiovascular benefit. ANG 1-7 signaling has been shown to be primarily mediated via the Mas receptor; however, numerous studies have shown that ANG 1-7 can also signal through the AT2 receptor, [33] [34] [35] most likely through transactivation of the receptor as the binding affinity of ANG 1-7 to the AT2 receptor is low. 36, 37 Furthermore, it has been also shown that although ANG 1-7 has an even lower binding affinity for the AT1 receptor, 36 some effects of ANG 1-7 can be mediated through a binding site that is losartan sensitive, suggesting that ANG 1-7 may also signal via the ACE-angiotensin II-AT1 receptor axis under certain conditions. 38, 39 The contributions of the AT1 and AT2 receptors to ANG 1-7-mediated vasodilation were not assessed in this study; thus, we cannot say with certainty that these receptor subtypes do not partially contribute to ANG 1-7-mediated signaling in the human microvasculature. A779, a specific Mas receptor antagonist, inhibited vasodilation >50% in both atrial and adipose arterioles, however, indicating that the Mas receptor is primarily responsible for effecting the actions of ANG 1-7 in these vascular beds.
Our findings that ANG 1-7 both exerts vasoprotection in a telomerase-dependent manner and directly increases telomerase activity in the human endothelium, coupled with the recent observation that telomerase activity is necessary to maintain NO-mediated dilation in the human microcirculation, 11 suggest that the ACE2-ANG 1-7-Mas receptor axis of the reninangiotensin system may be critically involved in promoting NO-mediated dilation in the human heart via modulation of telomerase activity. The direct mechanism by which ANG 1-7 modulates telomerase activity remains to be elucidated, but it is important to note that NO activates endothelial cell telomerase activity, 40, 41 and increased telomerase activity elevates NO production and endothelial nitric oxide synthase expression, 11 suggesting a potential feed-forward mechanism. Thus, studies aimed at elucidating the direct role of ANG 1-7-mediated NO generation on modulating telomerase activity would be valuable. If telomerase sits at a critical junction to regulate vascular health, 11, 42 it is likely that ANG 1-7 is one of many positive regulators of endothelial cell telomerase activity. For example, peroxisome proliferator-activated receptor-γ activators (thiazolidinediones) are well-studied agents that increase endothelial nitric oxide, 43, 44 improve vascular function in humans, 45, 46 and prevent atherosclerotic disease progression. 47 Although thiazolidinediones suppress telomerase Figure 4 . A, In human atrial vessels from coronary artery disease (CAD) subjects incubated overnight in cell culture media+PBS vehicle, polyethylene glycol (PEG) catalase significantly reduced flow-mediated dilation (FMD), whereas NG-nitro-l-arginine methyl ester (l-NAME) potentiated dilation, indicating that the primary mediator of vasodilation was H 2 O 2 . B, Overnight treatment with angiotensin (ANG) 1-7 (10 -9 mol/L) restored the nitric oxide (NO) component of FMD in atrial arterioles from subjects with CAD as l-NAME significantly reduced dilation, whereas PEG catalase had no effect. C, ANG 1-7 no longer restored the NO component of dilation when vessels were cotreated with the telomerase inhibitor 2-[[(2E)-3-(2naphthalenyl)-1-oxo-2-butenyl1-yl]amino] benzoic acid (BIBR-1532; 10 -5 mol/L) because l-NAME had no effect on dilation, whereas PEG catalase significantly reduced dilation. D, BIBR-1532 treatment alone had no effect on the mediator of FMD because PEG catalase reduced FMD similarly to untreated vessels. n=4 to 6, all groups. n indicates number of vessels, each from a different individual. *P<0.05 vs control. expression and activity in proliferating cell types, 48, 49 the opposite is observed in endothelial cells, 50 which are nonproliferating cells. In support of this, ex vivo rosiglitazone treatment is also sufficient to restore NO-mediated vasodilation in CAD adipose arterioles in a BIBR-1532-inhibitable manner ( Figure IV in the online-only Data Supplement). There is also evidence that chronic ANG 1-7 treatment increases peroxisome proliferator-activated receptor-γ expression in spontaneously hypertensive rats, 51 thus it is possible that peroxisome proliferator-activated receptor-γ may serve as a downstream signaling effector through which ANG 1-7 modulates endothelial cell telomerase activity.
As our data indicate, the increase in endothelial cell telomerase activity is because of a transcriptional increase in TERT, the catalytic subunit of telomerase. There are several regulatory layers that modulate TERT protein expression and activity, including transcriptional, 52,53 post-transcriptional, 54 and epigenetic 55 modifiers. Complete understanding of these pathways is still not defined (reviewed by Akincilar et al 56 ) . Future studies to decipher these complex interactions and their contribution to the development of cardiovascular disease are needed to completely understand how ANG 1-7, via TERT, contributes to the regulation of vascular tone in health and disease.
Study Limitations
It cannot be said with certainty if the difference in the magnitude of ANG 1-7-mediated dilation in vessels from CAD and non-CAD subjects is because of the presence of CAD itself or a combination of cardiovascular risk factors that contributed to the onset of the disease. For example, of the CAD subjects, 27 had hypertension, which is known to reduce ANG 1-7-mediated dilation in animals. 19 To determine which cardiovascular diseases reduce ANG 1-7-mediated dilation in the human microvasculature, larger, prospective studies would need to be undertaken. Similarly, a larger study would need to be performed to determine if age, sex, or adipose location affect microvascular dilation to ANG 1-7.
We also did not test the time course needed for ANG 1-7 to restore NO-mediated vasodilation in this study. Faria-Silva et al 57 showed in conscious Wistar rats that infusion of either ANG 1-7 or the Mas receptor agonist AVE0991 for as little as 30 minutes is sufficient to improve endothelial function in a NO-dependent manner. Overnight treatment with ANG 1-7 was chosen for our ex vivo studies to allow for sufficient time for transcription and translation of proteins that could be modulated by ANG 1-7 (such as TERT). Although a full examination of these mechanisms is beyond the scope of this study, it is important to note that treatment with ANG 1-7 for as little as 16 to 20 hours was sufficient to reverse a phenotype which took years to decades to develop, that is, CAD and the associated switch in vasodilator mechanism which favors H 2 O 2 . Because of the limited size of the human microvessels used in this study (each vessel has an approximate wet weight of 10 μg), we cannot accurately measure telomerase activity in the vessels. As a surrogate, we demonstrated that ANG 1-7 increases both TERT mRNA and protein expression, as well as telomerase activity in cultured human coronary artery endothelial cells. Because of the inability to accurately measure telomerase activity in human arterioles, we are also unable to say with certainty that telomerase activity was inhibited by BIBR-1532; however, the dose that was used (10 μmol/L) is more than 100-fold greater than the reported EC 50 by Damm and colleagues (93 nmol/L). 58 It is also important to note that BIBR-1532 was used at doses ≤ 50 μmol/L in that study, and no cytotoxic effects were observed.
